Home > Insider Trading > Filing (0001127602-13-017468)

Filing Details

Accession Number:: 0001127602-13-017468
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-05-17 17:42:16
Reporting Period:: 2013-05-16

Filing Date:: 2013-05-17
Accepted Time:: 2013-05-17 17:42:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1560565	M Cynthia Patton	One Amgen Center Drive Thousand Oaks CA 91320-1799	Svp & Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-05-16	900	$50.44	16,342	No	4	M	Direct
Common Stock	Acquisiton	2013-05-16	920	$58.43	17,262	No	4	M	Direct
Common Stock	Acquisiton	2013-05-16	1,724	$54.69	18,986	No	4	M	Direct
Common Stock	Disposition	2013-05-16	3,544	$105.01	15,442	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2013-05-16	900	$0.00	900	$50.44
Common Stock	Nqso (Right to Buy)	Disposition	2013-05-16	920	$0.00	920	$58.43
Common Stock	Nqso (Right to Buy)	Disposition	2013-05-16	1,724	$0.00	1,724	$54.69

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2013-04-28	2016-04-28	No	4	M	Direct
920	2013-04-26	2020-04-26	No	4	M	Direct
3,501	2013-04-25	2021-04-25	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	153	Indirect	401(k) Plan

Footnotes

The price reported is an average price. The prices ranged from $104.999 to $105.0415 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 132 RSUs which fully vest on 4/26/2014; 2,000 RSUs which vest in two equal annual installments of 1,000 each commencing 10/28/2013; 1,001 RSUs which vest in two installments of 493 and 508 on 4/25/2014 and 4/25/2015, respectively; 1,200 RSUs which vest in two equal installments of 396 each on 4/27/2014 and 4/27/2015 and one installment of 408 on 4/27/2016; 5,420 RSUs which vest in three installments of 1,788, 1,789 and 1,843 on 10/26/2014, 10/26/2015 and 10/26/2016, respectively; and 2,103 RSUs which vest in three installments of 693, 694 and 716 on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 82 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.